Search criteria | ||||
Cost-effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China | ||||
Ahmed Salem 1, Peng Men 2 3, Mafalda Ramos 4, Yan-Jun Zhang 5, Anastasia Ustyugova 6, Mark Lamotte 7 | ||||
1IQVIA, Real World Solutions, Zaventem 1930, Belgium. 2Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China. 3Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China. 4IQVIA, Global HEOR, Porto Salvo 2740-266, Portugal. 5Boehringer Ingelheim, Health Economics & Outcomes Research, Government Affairs & Market Access, Shanghai 200040, China. 6Boehringer Ingelheim, CardioMetabolism Respiratory, Ingelheim am Rhein 55216, Germany. 7IQVIA, Global HEOR, Zaventem 1930, Belgium. | ||||
Journal of Comparative Effectiveness Research 2021 https://doi.org/10.2217/cer-2020-0284. PMID: 33576249 DOI: 10.2217/cer-2020-0284 |
||||
, Article | ||||
, China | ||||
Abstract: https://pubmed.ncbi.nlm.nih.gov/33576249/ | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health economics | 2021 | English | , Clinical setting: Primary care, Cost effectiveness | |
Potential clinical and economic impact of optimised maintenance therapy on discharged patients with COPD after hospitalisation for an exacerbation in China | ||||
Ahmed Salem # 1, Heng Zhong # 2, Mafalda Ramos 1, Mark Lamotte 1, Hao Hu 3 | ||||
1Real World Evidence, IQVIA, Zaventem, Belgium. 2R&D China, AstraZeneca R&D, Shanghai, China. 3Institute of Chinese Medical Sciences, University of Macau, Macau, China haohu@um.edu.mo. #Contributed equally. | ||||
BMJ Open 2021;11:e043664. doi:10.1136/bmjopen-2020-043664 e043664. doi:10.1136/bmjopen-2020-043664 PMID: 33910947 PMCID: PMC8094343 DOI: 10.1136/bmjopen-2020-043664 |
||||
, Article | ||||
, Belgium, China | ||||
Abstract: https://pubmed.ncbi.nlm.nih.gov/33910947/ | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Respiratory disease | 2021 | English | , Clinical setting: Primary care, Cost effectiveness | |
The Burden Of Hpv In Head And Neck Cancers - Design Of The Broaden Study | ||||
Gómez Ulloa D1, Morais E2, Fenoll R1, Kothari S3, Giuliano A4, Mirghani H5, Mehanna H6, Waterboer T7, Roberts C3, Varga S3, Tu Y3, Pérez G3, Saah A3, Alemany L8 | ||||
1 IQVIA, Barcelona, Spain 2 MSD, CORE, Lyon, France 3 Merck & Co. Inc., Center for Observational and Real-world Evidence, Kenilworth, NJ, US 4 Moffitt Cancer Center and Research Institute, Center for Immunization and Infection Research in Cancer, Tampa, FL, US 5 HEGP, ORL, Paris, France 6 InHANSE, Head and Neck Surgery, Birmingham, UK 7 German Cancer Research Center (DKFZ), Infections and Cancer Epidemiology, Heidelberg, Germany 8 Catalan Institute of Oncology - IDIBELL, On behalf of Unit of Cancer and Infection in the Cancer Epidemiology Research Programme, Hospitalet Del Llobregat, Spain | ||||
IPVC, Barcelona, Spain, 23-27 March 2020 |
||||
, Oral presentation | ||||
, China, France, Germany, Italy, Japan, Portugal, Spain | ||||
Condition | Year | Language | Analysis type | |
, Infectious disease, Oncology | 2020 | English | , Burden of illness, Observational study, Retrospective Field Study | |
Projected long-term clinical benefit and cost-effectiveness of empagliflozin compared to glimepiride in patients with type 2 diabetes in China | ||||
Lamotte M1, Salem A2, Mettam S2, Ustyugova A2, Zhang YJ3, Ramos M1 | ||||
1 IQVIA, Zaventem, Belgium 2 Boehringer Ingelheim International, GmbH, Germany 3 Boehringer Ingelheim, Beijing, China | ||||
ADA, San Francisco, US, 07-11 June 2019 |
||||
, Poster | ||||
, China | ||||
Abstract: https://doi.org/10.2337/db19-1292-P | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2019 | English | , Cost effectiveness, Population Based Study | |
Contrasting three type 2 diabetes cardiovascular risk equations for East Asia with UKPDS82 using the IQIVA core diabetes model | ||||
Olivieri A1, Ramos M2, Monteiro S3, Altrabsheh E3, Gurjar K4, Lamotte M2 | ||||
1 IQVIA, Basel, Switzerland 2 IQVIA, Zaventem, Belgium 3 IQVIA, London, UK 4 IQVIA, Gurgaon, India | ||||
ISPOR, New Orleans, 18-22 May 2019 |
||||
, Poster | ||||
, China | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2019 | English | , Cost effectiveness, Population Based Study | |
Natural hisotry of oral human papillomavirus infection in healthy populations: Design of the Prevalence of Oral HPV infection, a Global assessment, THE PROGRESS STUDY | ||||
Pedros M1, Morais E2, Roset M1, Kothari S3, Alemany L5, Mirghani H6, Mehanna H7, Waterboer T8, Roberts C3, Vendetti N3, Walia A3, Drury R2, Luxembourg A3, Giuliano A9 | ||||
1 IQVIA, Barcelona, Spain 2 MSD, Lyon, France 3 Merck & Co, Inc., Kenilworth, NJ, US 5 Catalan Institute of Oncology, Cancer Epidemiology Research Program and IDIBELL i CIBERESP, Barcelona, Spain 6 Hôpital Européen Georges-Pompidou Université Paris-Descartes, Paris, France 7 Institute of Head & Neck Studies and Education (InHANSE), University of Birmingham, Birmingham, United kingdom 8 German Cancer Research Center (DKFZ), Heidelberg, Germany 9 Moffitt Cancer Center, Florida, US | ||||
EUROGIN, Monaco, France, 4-7 December 2019 |
||||
, Oral presentation | ||||
, China, France, Germany, Italy, Japan, Spain, UK, USA | ||||
Abstract: http://merck.creative.studios.s3-website-us-east-1.amazonaws.com/EUROGIN_2019/2019_EUROGIN_Pedros_NaturalHistory.pdf | ||||
Condition | Year | Language | Analysis type | |
, Clinical practice, Infectious disease, Methodology | 2019 | English | , Epidemiological study, Observational study, Population Based Study | |
Assessing the Burden of Type 2 Diabetes in China Considering the Current Status-Quo Management and Implications of Improved Management Using a Modeling Approach | ||||
Foos V1, Wang K2, McEwan P3, Zhang Y2, Xin P2, Jiang X2, Qu S4, Xiong T4, De Moor R1, Ramos M1, Lamotte M1, Ji L5 | ||||
1 IQVIA, Zaventem, Belgium 2 Lilly Suzhou Pharmaceutical Co, Ltd, Shanghai, China 3 Centre for Health Economics, Swansea University, Wales, England, UK 4 RWE Solutions & HEOR, QuintilesIMS, Shanghai, China 5 Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China | ||||
Value Health Reg Issues. 2019 May;18:36-46. |
||||
, Article | ||||
, China | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/30419449 | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health economics | 2019 | English | , Cost effectiveness | |
Cost-effectiveness of de-escalation from micafungin versus escalation from fluconazole for systemic candida infections in China | ||||
Dechang Chen, Xianyao Wan, Eliza Kruger, Can Chen, Xiaomeng Yue, Liang Wang, Jiuhong Wu | ||||
IQVIA, Department of Critical Care Medicine, Shanghai Ruijin Hospital Affiliated To Jiaotong University, School of Medicine, Shanghai | ||||
Journal of Medical Economics |
||||
, Article | ||||
, China | ||||
Abstract: http://www.tandfonline.com/doi/abs/10.1080/13696998.2017.1417312 | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Infectious disease | 2018 | English | , Cost effectiveness | |
Profiling and treatment patterns in NSCLC patients with CNS (brain) metastases in Europe and Asia | ||||
Mari E1, Mpima S2, Guglielmetti F1, Nasuti P2, Manuguid F2, Heitner Enschede S3 | ||||
1IQVIA , Milan, Italy 2IQVIA , London, UK 3IQVIA Inc, USA | ||||
, China, France, Germany, Italy, Japan, South Korea, Spain, UK | ||||
Abstract: http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e21085 | ||||
Condition | Year | Language | Analysis type | |
2018 | English | |||
Patterns of care and of biomolecular characterization of Right, Transverse, and Left Colorectal Cancer from real-life evidence in Asia Pacific and European countries | ||||
Ettore M1, Mpima S2, Guglielmetti F1, Nasuti P2 | ||||
1IQVIA , Milan, Italy 2IQVIA , London, UK | ||||
ESMO 2018 |
||||
, Poster | ||||
, China, France, Germany, Italy, Japan, South Korea, Spain, UK | ||||
Abstract: ESMO 2018 Congress | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2018 | English | ||
The health economic impact of optimizing post-hospitalization management for an exacerbation in COPD patients in China. | ||||
Salem A1, Ramos M1, Hu H2, Zhong H3, Lamotte M1 | ||||
1 IQVIA, Zaventem, Belgium 2 University of Macau, Macau, China 3 AstraZeneca, Shanghai, China | ||||
, Poster | ||||
, China | ||||
Abstract: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/83455 | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Respiratory disease | 2018 | English | , Cost analysis, Cost effectiveness | |
The health economic impact of optimizing post-hospitalization management for an exacerbation in COPD patients in China. | ||||
Salem A, Ramos M, Hu H, Zhong H, Lamotte M | ||||
IQVIA, Zaventem, Belgium | ||||
ISPOR Asia Pacific, 2018, September 8-11, Tokyo, Japan |
||||
, Poster | ||||
, China | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Respiratory disease | 2018 | English | , Cost effectiveness | |
Patterns of Therapy in Regional Lymph Node Positive Prostate Cancer in Europe and Asia: An International Analysis | ||||
Prentice M1, Mpima S2, Martinez de Pinillos A2, Nasuti P2, Davda R, Payne H 1 | ||||
1 University College Hospital, London, UK 2 IQVIA , London, UK | ||||
ESMO 2018 |
||||
, Poster | ||||
, China, France, Germany, Italy, Japan, South Korea, Spain, UK | ||||
Abstract: ESMO 2018 Congress | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2018 | English | ||
Initial Management of localised prostate cancer in the Elderly: An International Data Review | ||||
Prentice M1, Mpima S2, Martinez de Pinillos A2, Nasuti P2, Davda R1, Payne H1 | ||||
1 University College Hospital, London, UK 2 IQVIA , London, UK | ||||
SIOG 2018 |
||||
, Poster | ||||
, China, France, Germany, Italy, Japan, South Korea, Spain, UK | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2018 | English | ||
Profiling and treatment patterns in NSCLC patients with CNS (brain) metastases in Europe and Asia | ||||
Mari E1, Mpima S2, Guglielmetti F1, Nasuti P2, Manuguid F2, Heitner Enschede S3 | ||||
1IQVIA , Milan, Italy 2IQVIA , London, UK 3IQVIA Inc, USA | ||||
JCO ( ASCO 2018) |
||||
, Abstract | ||||
, Asia Pacific, China, Europe, France, Germany, Italy, Japan, South Korea, Spain, UK | ||||
Abstract: http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e21085 | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2018 | English | ||
Assessing the economic burden of type 2 diabetes in China reflecting the current standard of the disease management and for improved management scenarios using a modeling approach. | ||||
Foos V1, Lamotte M1, McEwan P4, Jiang X3, Zhang YL3, Qu S2, De Moor R1, Ramos R1, Xiong T2, Wang K3 | ||||
1 IMS Health, Brussels, Belgium 2 IMS Health, Shanghai, China 3 Eli Lilly, Shanghai, China 4 Swansea University, Wales | ||||
22nd ISPOR Annual International Meeting, 2017, May 20-24, Boston, MA, USA |
||||
, Abstract | ||||
, China | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2017 | English | , Cost effectiveness | |
THE ANALYSIS OF INPATIENTS COST OF BREAST CANCER IN CHINA, 2011 | ||||
Song S, Wang Z, Zhang M | ||||
IMS consulting group, Shanghai, China | ||||
ISPOR 18th Annual European Congress Milan, Italy November, 2015 |
||||
, Poster | ||||
, China | ||||
Condition | Year | Language | Analysis type | |
, Mental health, Oncology | 2015 | English | ||
Cost-Effectiveness of Linezolid versus Vancomycin among Patients with Methicillin-Resistant Staphylococcus aureus Confirmed Nosocomial Pneumonia in China | ||||
Tan S1, Wang X2, Wu B3, Kang H4, Li Q5, Chen Y6, Chen C6, Hajek P7, Patel D8, Gao X8 | ||||
1IMS Health, Singapore | ||||
Value in Health, Volume 3, May 2014, Pages 94–100 |
||||
, Article | ||||
, China | ||||
Abstract: http://www.sciencedirect.com/science/article/pii/S221210991400017X | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2014 | English | , Cost effectiveness | |
HTA, budget impact tools and international price referencing from China’s perspective: what are the current developments and future considerations? | ||||
Koh L1, Li SC2, Zhang M3, Glaetzer C1 | ||||
1 Johnson & Johnson, Singapore, Singapore 2 School of Biomedical Sciences & Pharmacy, University of Newcastle, Callaghan, Australia 3 IMS Consulting, Shanghai, China | ||||
ISPOR 6th Asia-Pacific Conference, Beijing, China, 6-9 September, 2014 |
||||
, Panel presentation | ||||
, China | ||||
Condition | Year | Language | Analysis type | |
, Pricing and reimbursement | 2014 | English | , Pricing & Reimbursement | |
Afatinib in the treatment of EGFR mutation-positive NSCLC - A network meta-analysis. | ||||
Popat S1, Mok T2, Yang JC3, Wu YL4, Lungershausen J5, Stammberger U5, Griebsch I5, Fonseca T6, Paz-Ares L7 | ||||
1Royal Marsden Hospital, London, UK. 2State Key Laboratory of Southern China, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong. 3National Taiwan University, Taipei, Taiwan. 4Guangdong Lung Cancer Institute, Guangzhou, China. 5Boehringer Ingelheim GmbH, Ingelheim, Germany. 6IMS Health, London, UK. 7Instituto de Biomedicina de Sevilla - IBIS (University Hospital Virgen del RocÃo, US, CSIC), Seville, Spain. | ||||
Lung Cancer. 2014 Aug;85(2):230-8 |
||||
, Article | ||||
, China, Germany, Hong Kong, Spain, Taiwan, UK | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/24929780 | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2014 | English | , Meta analysis | |
Evolution of oral anticancer treatments use in France from 2004 to 2012: the Re-ACTOR Study. | ||||
Benjamin L, Maurel F, Bardoulat I, Ricarte C | ||||
1 Glaxosmithkline, 2 Health Economics and Outcomes Research, Marly le Rol, France, 3 IMS Health, La Defense, France | ||||
ISPOR Europe 2013 Annual meeting |
||||
, Poster | ||||
, China, France, Germany, Italy, Japan, Korea, Spain, Taiwan, UK | ||||
Abstract: http://www.valueinhealthjournal.com/article/S1098-3015(13)02489-3/fulltext | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2013 | English | , Retrospective database analysis | |
Current situation of oral anticancer treatments use in France: the ACTOR Study. | ||||
Benjamin L, Maurel F, Bardoulat I, Ricarte C | ||||
1 Glaxosmithkline, 2 Health Economics and Outcomes Research, Marly le Rol, France, 3 IMS Health, La Defense, France | ||||
ISPOR Europe 2013 Annual meeting |
||||
, Abstract | ||||
, China, France, Germany, Italy, Japan, Korea, Spain, Taiwan, UK | ||||
Abstract: http://www.valueinhealthjournal.com/article/S1098-3015(13)02492-3/fulltext | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2013 | English | ||
Medical resource use and associated costs in open-angle glaucoma in 10 Asia-pacific countries. | ||||
Gerlier L1, Lamotte M1, Caputo J2, Tan R3 | ||||
1 IMS Health Consulting EMEA, Vilvoorde, Belgium 2 IMS Health Consulting Asia-Pacific, Singapore 3 ALCON, Asia-Pacific, Singapore | ||||
5th ISPOR Asia-Pacific Conference, 2012, September 2-4, Taipei, Taiwan |
||||
, Abstract, Poster | ||||
, Australia, China, Hong Kong, India, Malaysia, New Zealand, Singapore, South Korea, Taiwan, Thailand | ||||
Condition | Year | Language | Analysis type | |
, Ophthalmology | 2012 | English | , Burden of illness | |
Direct medical costs of Diabetes Mellitus in China: Annual cost of illness and long-term projections using a validated diabetes model | ||||
Palmer JL1, Caputo J2, Foos V1, Grant D3, Lamotte M4, Lloyd A3, McEwan P5 | ||||
1 IMS Health, Basel, Switzerland, 2 IMS Health, Singapore, Singapore, 3 IMS Health, London, UK, 4 IMS Health Consulting Group, Vilvoorde, Belgium, 5 HEOR Consulting, Monmouth, Monmouthshire, UK | ||||
ISPOR 5th Asia-Pacific Conference, Taipei, Taiwan, September 2nd – 4th 2012 |
||||
, Poster | ||||
, China | ||||
Abstract: http://www.ispor.org/conferences/Taipei0912/Posters2.aspx | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2012 | English | , Cost of illness | |
Usage of Self-Monitoring of Blood Glucose (SMBG) by Diabetes Therapy Type in Larger Cities in China. | ||||
Mast O1, Tan A2, Zweyer S2, Perridy D2. | ||||
1Roche, Mannheim, Germany 2Cegedim Strategic Data, Shanghai, China | ||||
ISPOR 5TH ASIA-PACIFIC CONFERENCE , TAIPEI, TAIWAN |
||||
, Poster | ||||
, China | ||||
Abstract: http://www.valueinhealthjournal.com/article/S1098-3015(12)01865-7/abstract | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2012 | English | , Compliance, Retrospective database analysis | |
UTILIZATION OF FPG, HBA1C AND SELF-MONITORING OF BLOOD GLUCOSE (SMBG) IN COMMUNITY HEALTH CENTERS IN THE SHANGHAI AREA. | ||||
Mast O1, Tan A2 | ||||
1Roche, Mannheim, Germany 2Cegedim Strategic Data, Shanghai, China | ||||
ISPOR 5TH ASIA-PACIFIC CONFERENCE, TAIPEI, TAIWAN |
||||
, Poster | ||||
, China | ||||
Abstract: http://www.valueinhealthjournal.com/article/S1098-3015(12)01866-9/abstract | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2012 | English | , Compliance, Survey research | |
Real World Patient Profile of Patients with Reduced Ejection Fraction Heart Failure (HF-REF) in 5 Regions of China. | ||||
Li XY, Crawford B, Liao YH, Tanaka E, Wang D, Sung J, Zheng J, McDonald J. | ||||
ISPOR (June 2 – 6, 2012, Washington DC |
||||
, Poster | ||||
, China | ||||
Abstract: http://www.valueinhealthjournal.com/article/S1098-3015(12)00765-6/abstract | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease | 2012 | English | ||
Design and rationale of the HCC BRIDGE study in China: a longitudinal, multicenter cohort trial in hepatocellular carcinoma. | ||||
Chen M1, Therneau T, Orsini LS, Qiao YL. | ||||
Department of Hepatobiliary Surgery, Sun Yat-Sen University Cancer Center, Guangdong Province, China | ||||
BMC Gastroenterol. 2011 May 12;11:53 |
||||
, Article | ||||
, China | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3115904/ | ||||
Condition | Year | Language | Analysis type | |
, Oncology | 2011 | English | , Clinical setting: hospital, Retrospective cohort analysis | |
Clinical and cost effectiveness of biphasic insulin aspart 30 once or twice daily versus insulin glargine in type 2 diabetes mellitus: a modeling analysis in the Chinese setting | ||||
Palmer JL1, Beaudet A1, White,J2, Plun-Favreau J3,Smith-Palmer J1 | ||||
1 IMS Health, Basel, Switzerland; 2 Novo Nordisk I/O, Zurich, Switzerland; 3 Novo Nordisk A/S, Copenhagen, Denmark | ||||
ISPOR 4th Asia-Pacific Conference, 5-7 September 2010, Hilton Phuket, Phuket, Thailand |
||||
, Poster | ||||
, China | ||||
Abstract: http://www.ispor.org/conferences/Phuket0910/posters.aspx | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2010 | English | , Cost effectiveness | |
Cost-Effectiveness of Biphasic Insulin Aspart versus Insulin Glargine in Patients with Type 2 Diabetes in China | ||||
Palmer JL1, Beaudet A1, White J2, Plun-Favreau J3, Smith‑Palmer J1 | ||||
1 IMS Health, Theaterstrasse 4, 4051, Basel, Switzerland 2 Novo Nordisk I/O, Zurich, Switzerland 3 Novo Nordisk A/S, Copenhagen, Denmark | ||||
Adv Ther. 2010 Nov;27(11):814-27 |
||||
, Manuscript in preparation | ||||
, China | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21061114 | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2010 | English | , Cost effectiveness | |
Cost-Effectiveness of Switching to Biphasic Insulin Aspart in Poorly-Controlled Type 2 Diabetes Patients in China | ||||
Palmer JL1, Gibbs M2, Scheijbeler H3, Kotchie R3, Nielsen S4, White J5, Valentine WJ1 | ||||
1IMS Health, Basel, Switzerland, 2IMS Health, Shanghai, China, 3IMS Health, London, UK, 4Novo Nordisk A/S, Bagsværd, Denmark, 5Novo Nordisk International Operations A/S, Zurich, Switzerland | ||||
Adv Ther. 2008 Aug;25(8):752-74. |
||||
, Article | ||||
, China | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2008 | English | , Cost effectiveness | |
Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analyses in a Chinese setting. | ||||
Chen X1, Clegg JP2, Chen L1, Yu H3, Wittrup-Jensen KU4, Valentine WJ1 | ||||
1Fu Dan University, Shanghai, China, 2IMS Health, Basel, Switzerland, 3Bayer Healthcare Co. Ltd, Shanghai, China, 4Bayer Schering Pharma AG, Berlin, Germany | ||||
3rd Asia-Pacific Conference, 7-9 September 2008 |
||||
, Oral presentation | ||||
, China | ||||
Abstract: http://www.ingentaconnect.com/content/apl/cmro/2006/00000022/00000007/art00019?token=006718db3e1a03ae72752d455e4e2663433b393f6a3340257d7241255e437a63736a425b6b674c58662a702c2e6e49625371e31 | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2008 | English | , Cost effectiveness | |
Cost-effectiveness of biphasic insulin aspart 30 versus human premix insulin for type 2 diabetes patients in China | ||||
Lynch M1, Scheijbeler HW2, Kotchie R2, Valentine WJ3, Nielsen S4, White J5 | ||||
1IMS Health, Shanghai, China; 2IMS Health, London, UK; 3 IMS Health, Basel, Switzerland; 4Novo Nordisk, Bagsværd, Denmark; 5Novo Nordisk, Zürich, Switzerland | ||||
ISPOR 2007 10th Annual European Congress, Athens, Greece, 8 – 11 November 2008 |
||||
, Poster | ||||
, China | ||||
Condition | Year | Language | Analysis type | |
, Diabetes | 2007 | English | , Cost effectiveness | |
Asthma control and its direct healthcare costs: findings using a derived Asthma Control Test (ACT) score in eight Asia-Pacific areas. | ||||
Lai CKW1 Kuo S-H2 de Guia T3 Lloyd A4, Williams AE5, Spencer MD5 | ||||
1 Dept of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong 2 National Taiwan University Hospital, Taipei, Taiwan 3 Philippine Heart Centre, Quezon City, The Philippines 4 Fourth Hurdle Consulting Ltd, London, UK 5 GlaxoSmithKine R&D, Greenford, UK | ||||
European Respiratory Review 2006; 15:(98): 24-29 |
||||
, Manuscript in preparation | ||||
, China, Hong Kong, Malaysia, Philippines, Singapore, Taiwan, Vietnam | ||||
Condition | Year | Language | Analysis type | |
, Respiratory disease | 2006 | English | , Cost of illness | |
Potential savings with everolimus with reduced-dose cyclosporine compared to mycophenolate motefil with full dose cyclosporine in de novo renal transplant recipients in China. | ||||
Yang X, Ethgen O, Wang W, Lian R, Ricci JF, Spaepen E et al. | ||||
ISPOR 2nd Asia-Pacific Congress, Shanghai, China |
||||
, Poster | ||||
, China | ||||
Condition | Year | Language | Analysis type | |
, Nephrology | 2006 | English | ||